Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 38, 2013, Pages 15401-15406

  Hu, Yang ^a   Chen, Ying ^a,b   Ding, Lexi ^a,c   He, Xuemin ^a   Takahashi, Yusuke ^b   Gao, Yang ^a,d   Shen, Wei ^a,e   Cheng, Rui ^a   Chen, Qian ^a   Qi, Xiaoping ^f   Boulton, Michael E ^f   Ma, Jian Xing ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e JILIN UNIVERSITY   (China)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRYPSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY; CELL LOSS; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOSTASIS; MALE; MICROANGIOPATHY; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA; RETINA BLOOD VESSEL; RETINA CAPILLARY; RETINA CELL; RETINITIS; ANIMAL; CAPILLARY PERMEABILITY; CELL CULTURE; GENETICS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MUS; RATTUS;

ANIMALS; BLOTTING, WESTERN; CAPILLARY PERMEABILITY; CELLS, CULTURED; DIABETIC RETINOPATHY; DOWN-REGULATION; GLUCOSE; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; PPAR ALPHA; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RETINA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRYPSIN;

EID: 84884343947     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1307211110     Document Type: Article

References (42)

1. Michalik L, et al. (2006) International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58(4):726-741.
2. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53: 409-435.
3. Filip-Ciubotaru F, Foia L, Manciuc C, Grigore C (2011) [PPARs: Structure, mechanisms of action and control. Note I]. Rev Med Chir Soc Med Nat Iasi 115(2):477-484.
4. Cuzzocrea S, et al. (2006) The role of the peroxisome proliferator-activated receptoralpha (PPAR-alpha) in the regulation of acute inflammation. J Leukoc Biol 79(5): 999-1010.
5. Duval C, Fruchart JC, Staels B (2004) PPAR alpha, fibrates, lipid metabolism and inflammation. Arch Mal Coeur Vaiss 97(6):665-672.
6. Kasai T, Miyauchi K, Yokoyama T, Aihara K, Daida H (2006) Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models. Atherosclerosis 188(2):274-280.
7. Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347(6294):645-650.
8. Dreyer C, et al. (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68(5):879-887.
9. Miyachi H, Uchiki H (2003) Analysis of the critical structural determinant(s) of speciesselective peroxisome proliferator-activated receptor alpha (PPAR alpha)-activation by phenylpropanoic acid-type PPAR alpha agonists. Bioorg Med Chem Lett 13(19): 3145-3149.
10. Liu J, et al. (2011) PPAR-α agonist fenofibrate upregulates tetrahydrobiopterin level through increasing the expression of guanosine 5'-triphosphate cyclohydrolase-I in human umbilical vein endothelial cells. PPAR Res 2011:523520.
11. Castillero E, et al. (2011) Fenofibrate, a PPARalpha agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy. Am J Physiol Endocrinol Metab 300(5):E790-E799.
12. Hanssen KF (1997) Blood glucose control and microvascular and macrovascular complications in diabetes. Diabetes 46(Suppl 2):S101-S103.
13. Maji D (2004) Prevention of microvascular and macrovascular complications in diabetes mellitus. J Indian Med Assoc 102(8):426-, 428, 430 passim.
14. Hiukka A, Maranghi M, Matikainen N, Taskinen MR (2010) PPARalpha: An emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 6(8): 454-463.
15. Tandon N, Ali MK, Narayan KM (2012) Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: Implications of the results of recent clinical trials in type 2 diabetes. Am J Cardiovasc Drugs 12(1):7-22.
16. Keech AC, et al.; FIELD study investigators (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 370(9600):1687-1697.
17. Ginsberg HN, et al.; ACCORD Study Group (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362(17):1563-1574.
18. Park CW, et al. (2006) Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 55(4):885-893.
19. Chen Y, et al. (2013) Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes 62(1):261-272.
20. Goetze S, et al. (2002) PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 293(5):1431-1437.
21. Barak Y, Sadovsky Y, Shalom-Barak T (2008) PPAR signaling in placental development and function. PPAR Res 2008:142082.
22. Takeyama K, Kodera Y, Suzawa M, Kato S (2000) [Peroxisome proliferator-activated receptor(PPAR)-structure, function, tissue distribution, gene expression]. Nihon Rinsho 58(2):357-363.
23. Kawada T (1998) [Lipid metabolism related nuclear receptor-the structure, function, expression and classification of peroxisome proliferation-activated receptor (PPAR)]. Nihon Rinsho 56(7):1722-1728.
24. Wang F, et al. (2008) Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol. Can J Physiol Pharmacol 86(7):465-471.
25. Hegarty BD, Furler SM, Oakes ND, Kraegen EW, Cooney GJ (2004) Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo-a study using the novel PPARalpha/gamma agonist tesaglitazar. Endocrinology 145(7):3158-3164.
26. Araújo CV, et al. (2012) PPAR gamma activation protects the brain against microvascular dysfunction in sepsis. Microvasc Res 84(2):218-221.
27. Madonna R, et al. (2011) Omega-3 fatty acids attenuate constitutive and insulininduced CD36 expression through a suppression of PPAR α/γ activity in microvascular endothelial cells. Thromb Haemost 106(3):500-510.
28. Biscetti F, et al. (2008) Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 57(5):1394-1404.
29. Hsueh WA, Jackson S, Law RE (2001) Control of vascular cell proliferation and migration by PPAR-gamma: A new approach to the macrovascular complications of diabetes. Diabetes Care 24(2):392-397.
30. Narravula S, Colgan SP (2001) Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-activated receptor alpha expression during hypoxia. J Immunol 166(12):7543-7548.
31. Fujita T, et al. (2013) Complement-mediated chronic inflammation is associated with diabetic microvascular complication. Diabetes Metab Res Rev 29(3):220-226.
32. Tang J, Kern TS (2011) Inflammation in diabetic retinopathy. Prog Retin Eye Res 30(5): 343-358.
33. Shi G, et al. (2008) Control of chemokine gradients by the retinal pigment epithelium. Invest Ophthalmol Vis Sci 49(10):4620-4630.
34. Eichler W, Yafai Y, Wiedemann P, Reichenbach A (2004) Angiogenesis-related factors derived from retinal glial (Müller) cells in hypoxia. Neuroreport 15(10):1633-1637.
35. Holtkamp GM, Kijlstra A, Peek R, de Vos AF (2001) Retinal pigment epitheliumimmune system interactions: Cytokine production and cytokine-induced changes. Prog Retin Eye Res 20(1):29-48.
36. Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y (2008) PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci 82(15-16):884-891.
37. Hertz R, Bar-Tana J (1998) Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans. Toxicol Lett 102-103:85-90.
38. Varet J, et al. (2003) Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 60(4):810-819.
39. Chen Y, et al. (2009) Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol 175(6):2676-2685.
40. Hu Y, et al. (2013) Pathogenic role of the Wnt signaling pathway activation in laserinduced choroidal neovascularization. Invest Ophthalmol Vis Sci 54(1):141-154.
41. Cogan DG, Kuwabara T (1984) Comparison of retinal and cerebral vasculature in trypsin digest preparations. Br J Ophthalmol 68(1):10-12.
42. Michael JC, De Venecia G (1995) Retinal trypsin digest study of cystoid macular edema associated with peripheral choroidal melanoma. Am J Ophthalmol 119(2):152-156.